Glioblastoma is a formidable brain malignancy known for its rapid growth and insensitivity to conventional treatments. Investigations are constantly underway to identify new therapeutic strategies, and recently, a novel biomarker named LCA168 has emerged as a potential avenue for GBM treatment. LCA168 is a protein that is abundantly produced in gl